AstraZeneca (AZN) Tops Q1 EPS by $1.06

AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $1.89, $1.06 better than the analyst estimate of $0.83. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $10.99 billion.

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small ce
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Yalla Group Limited (YALA) Reports Q2 EPS of $0.24